4//SEC Filing
Zuraw Qing Che 4
Accession 0002079210-25-000003
CIK 0001817229other
Filed
Dec 8, 7:00 PM ET
Accepted
Dec 9, 8:00 AM ET
Size
14.6 KB
Accession
0002079210-25-000003
Insider Transaction Report
Form 4
Zuraw Qing Che
Chief Development Officer
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2025-12-05−218,652→ 0 totalExercise: $47.60Exp: 2035-07-16→ Common Stock (218,652 underlying) - Award
Employee Stock Option (right to buy)
2025-12-05+218,652→ 218,652 totalExercise: $8.18Exp: 2035-07-16→ Common Stock (218,652 underlying)
Footnotes (4)
- [F1]On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The amounts herein reflect the reverse stock split.
- [F2]On December 5, 2025, pursuant to the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of December 5, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 4 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- [F3]1/4th of the shares underlying the option vest on July 17, 2026, with the remainder vesting in substantially equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date.
- [F4]The exercise price of the stock option award is $8.18 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 24 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the Inducement Plan); and (iii) 30 days prior to the option's original expiration date.
Documents
Issuer
Vor Biopharma Inc.
CIK 0001817229
Entity typeother
Related Parties
1- filerCIK 0002079210
Filing Metadata
- Form type
- 4
- Filed
- Dec 8, 7:00 PM ET
- Accepted
- Dec 9, 8:00 AM ET
- Size
- 14.6 KB